Physician profile
Michael T Lavelle
NPI 1881635779
$3,204.57
in general payments reported to CMS, 2019-2025
31 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,164 · 2020: $275 · 2021: $232 · 2022: $511 · 2023: $591 · 2024: $254 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $779 · Travel and Lodging: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.48 |
| Travel and Lodging | $243.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $656.13 | 2019-2025 | Padcev, Myrbetriq |
| Teleflex LLC | $260.55 | 2021-2023 | Urolift |
| Antares Pharma, INC. | $183.56 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Abbvie INC. | $180.88 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $159.67 | 2019-2023 | |
| Pfizer INC. | $156.98 | 2019-2025 | |
| Allergan, INC. | $148.25 | 2019-2020 | |
| Boston Scientific Corporation | $134.41 | 2019-2021 | |
| Procept Biorobotics Corporation | $125.54 | 2024 | Aquabeam System |
| Myriad Genetic Laboratories, INC. | $105.99 | 2021-2023 | Prolaris |
| Dendreon Pharmaceuticals LLC | $104.53 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $102.39 | 2022 | |
| Ferring Pharmaceuticals INC. | $96.61 | 2019 | |
| Janssen Biotech, INC. | $90.72 | 2019 | |
| Endo Pharmaceuticals INC. | $84.50 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $73.28 | 2024 | (Am5) Lead Management |
| Coloplast Corp | $67.14 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $61.23 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $54.40 | 2019 | |
| Convatec INC. | $47.68 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $45.17 | 2019 | |
| Biosense Webster, INC. | $38.41 | 2024-2025 | Qdot Micro Catheter, Carto 3 |
| Amgen INC. | $37.03 | 2019 | |
| Myovant Sciences INC. | $37.02 | 2021 | |
| Travere Therapeutics, INC. | $30.33 | 2019-2021 | |
| Olympus America INC. | $29.26 | 2025 | Itind System |
| Halozyme INC | $25.56 | 2023 | |
| Karl Storz Endoscopy-America | $25.37 | 2019 | |
| Blue Earth Diagnostics | $16.70 | 2021 | |
| Ambu INC. | $13.33 | 2023 | |
| Alnylam Pharmaceuticals INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lavelle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.